Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Tuberculosis
•
Pulmonology
•
Pulmonary Infections
How do you approach a positive IGRA in a patient with idiopathic NSIP needing a prolonged course of corticosteroid therapy and a prior history MAC in a single sputum culture?
Related Questions
Under what circumstances would you choose the 1-month 1HP treatment over a 3-4 month regimen for latent TB?
How would you manage a patient with necrotizing pneumonia due to a susceptible Pseudomonas aeruginosa strain who continues to have significant purulent secretions and worsening imaging while receiving cefepime?
Do you treat complicated pneumonia with a drained empyema longer if Streptococcus anginosus is cultured, either in isolation or with other organisms, compared to cases in which it is not?
How do you or your practice manage young, average-risk patients without structural lung disease referred to you or self-referred for concern of environmental mold exposure?
How do you balance diagnostic stewardship and high value cost-conscious care when working up a patient with newly diagnosed HIV/AIDS admitted to the ICU with shortness of breath who most likely has PJP pneumonia or cryptococcal infection but is at risk of multiple other pathogens?
Would you recommend early empirical anti-mold therapy for patients with severe influenza pneumonia admitted to the ICU to reduce the incidence of influenza-associated pulmonary aspergillosis?
Do you prescribe empiric antibiotics to patients with CAP who test positive for a respiratory virus?
What is your typical approach to antibiotic management for severe necrotizing MSSA pneumonia with concurrent MSSA bacteremia assuming no overt antibiotic contraindications and TTE without evidence of endocarditis?
Have you incorporated the use of MycoTOX profiles into your clinical practice and, if so, in what capacity?
How would you approach troponin testing and cardiac monitoring for hospitalized patients with Mycoplasma pneumonia, given recent findings of significant cardiac involvement?
